MINNEAPOLIS--(BUSINESS WIRE)--Dr. Ronald M. Fairman, principal investigator for the VALOR clinical study evaluating the Talent™ Thoracic Stent Graft System, today presented positive 12-month results at a late-breaking session during the annual meeting of the Society for Vascular Surgery in Baltimore. Sponsored by Medtronic (NYSE:MDT), VALOR is a prospective, multi-center study of 195 test group patients with thoracic aortic aneurysms who were considered candidates for open surgical repair. The primary endpoint is “all cause” mortality at 12 months, comparing minimally invasive endovascular stent graft treatment to a historical surgical control group.
